secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
CIK:        0001335105
Form:       8-K
Filed at:   2025-12-23T23:59:59+00:00
Accession:  0001493152-25-028999
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lixte expands ovarian cancer trial to 42 patients; expects initial data in H1 2026
--------------------------------------------------------------------------------

- Amendment No.2 to collaborative study doubles enrollment from 21 to 42 patients for LB-100 + dostarlimab trial in ovarian clear cell carcinoma.
- Lixte enters new Collaborative Research Agreement with MD Anderson; pays milestone payments up to $1.5M ($500k per event) plus 3.75% royalty on net profit.
- GSK and Lixte provide drugs at no cost to institution for expanded 42-patient study; no additional GSK payments beyond original 21 subjects.
- Initial data from first 21 patients expected in first half of 2026; trial led by MD Anderson includes Northwestern as second site.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1335105/000149315225028999/0001493152-25-028999-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1335105/000149315225028999/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-028999

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer